Skip to main content
Premium Trial:

Request an Annual Quote

GPC, ICOS Strike Antibody Agreement

NEW YORK, Nov. 26 — GPC Biotech has signed an agreement to allow ICOS Corporation to develop and manufacture its anti-MHC class II antibody products, GPC said on Monday.

 

Terms of the arrangement call for ICOS, of Bothell, Wash., to conduct large-scale production of the two antibodies through a non-exclusive license to its mammalian cell-expression technology. GPC Biotech will retain rights to develop and commercialize the product.

Financial details of the deal were not disclosed.

 

GPC Biotech, a genomics and proteomics company based in Martinsried/Munich, Germany, identified these therapeutic antibody products with affinity for the MHC class II target through a research partnership with MorphoSys, also based in Martinsried/Munich.

 

One product is being developed as a potential treatment for certain types of B-cell lymphoma and the other may be an effective therapy for suppressing T-cell responses in the treatment of transplant rejection and graft-versus-host disease, GPC said. The antibodies were generated from MorphoSys' combinatorial antibody library.

 

Two weeks ago, GPC Biotech said that two new alliances have helped boost its third-quarter revenues by 65 percent to 3.5 million euros, or roughly $3.1 million, from 2.1 million euros in the year-ago period.

 

During the first nine months of the year, the company reported a 58 percent increase in research and development expenses to 23.4 million euros. GPC said that expenses from such activities totalled 14.8 million euros in the third quarter but did not offer a figure for the corresponding period in 2000.

The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.